2023 World Conference on Lung Cancer (Posters)-EP10.01. Efficacy and Safety of Nintedanib and Docetaxel in Patients with Lung Adenocarcinoma: A Multicenter Real-world Analysis

EP10.01. Efficacy and Safety of Nintedanib and Docetaxel in Patients with Lung Adenocarcinoma: A Multicenter Real-world Analysis - PDF(Abstract)

Back to course

Pdf Summary

This study aimed to evaluate the efficacy and safety of nintedanib and docetaxel in patients with advanced/metastatic lung adenocarcinoma. The primary endpoints were progression-free survival (PFS) and best objective response, and overall survival was a secondary endpoint. The data were sourced from two centers in Slovenia and one in Croatia, with 96 patients retrospectively analyzed after treatment with chemotherapy and immune checkpoint inhibitor failure.<br /><br />The results showed that the median PFS across all lines of treatment was 3.0 months, and the median overall survival was 8.0 months. The objective response rate was 18.8%, and the disease control rate was 57.3%. Among patients who received docetaxel plus nintedanib as third-line therapy, the ORR was 19.1% and the DCR was 57.4%. The highest response rate was observed in patients who received second-line docetaxel plus nintedanib after first-line combination chemotherapy-immune checkpoint inhibitor therapy, with an ORR of 29.2% and DCR of 66.7%. The median PFS for this subgroup of patients was 4.0 months.<br /><br />Adverse events were experienced by 55.2% of patients, with the most frequent being gastrointestinal (diarrhea) and increased liver enzyme levels.<br /><br />In conclusion, the combination of nintedanib and docetaxel showed efficacy and an acceptable safety profile in patients with advanced pulmonary adenocarcinoma after chemotherapy-ICI failure. This treatment modality could be considered effective and offers a new strategy for these patients.

Asset Subtitle

Marko Jakopovic

Meta Tag

Speaker Marko Jakopovic

Topic Metastatic NSCLC: Cytotoxic Therapy

Keywords

efficacy

safety

nintedanib

docetaxel

lung adenocarcinoma

progression-free survival

objective response

overall survival

chemotherapy

immune checkpoint inhibitor